William Blair Reaffirms “Outperform” Rating for Verve Therapeutics (NASDAQ:VERV)

Verve Therapeutics (NASDAQ:VERV)‘s stock had its “outperform” rating reaffirmed by research analysts at William Blair in a report issued on Friday,RTT News reports.

A number of other equities analysts also recently commented on VERV. Canaccord Genuity Group upped their price objective on shares of Verve Therapeutics from $29.00 to $32.00 and gave the stock a “buy” rating in a research report on Wednesday, November 6th. Royal Bank of Canada cut their price objective on shares of Verve Therapeutics from $20.00 to $17.00 and set an “outperform” rating for the company in a research report on Wednesday, November 6th. Finally, HC Wainwright lowered their price target on shares of Verve Therapeutics from $15.00 to $14.00 and set a “buy” rating on the stock in a research note on Wednesday, November 6th. Five investment analysts have rated the stock with a buy rating, According to data from MarketBeat, Verve Therapeutics presently has an average rating of “Buy” and a consensus price target of $25.75.

Verve Therapeutics Trading Down 7.0 %

Shares of Verve Therapeutics stock traded down $0.55 during trading on Friday, reaching $7.28. The company’s stock had a trading volume of 1,176,519 shares, compared to its average volume of 1,557,203. The company has a 50-day moving average price of $6.80 and a two-hundred day moving average price of $5.96. The firm has a market cap of $616.32 million, a PE ratio of -2.96 and a beta of 1.74. Verve Therapeutics has a fifty-two week low of $4.30 and a fifty-two week high of $19.34.

Institutional Investors Weigh In On Verve Therapeutics

A number of large investors have recently added to or reduced their stakes in VERV. BVF Inc. IL grew its stake in Verve Therapeutics by 962.2% in the 4th quarter. BVF Inc. IL now owns 6,904,050 shares of the company’s stock valued at $38,939,000 after acquiring an additional 6,254,050 shares during the last quarter. Point72 Asset Management L.P. purchased a new position in Verve Therapeutics in the 4th quarter valued at about $7,863,000. Schonfeld Strategic Advisors LLC lifted its holdings in shares of Verve Therapeutics by 57.4% during the 4th quarter. Schonfeld Strategic Advisors LLC now owns 3,789,379 shares of the company’s stock worth $21,372,000 after acquiring an additional 1,382,176 shares during the period. State Street Corp lifted its holdings in shares of Verve Therapeutics by 27.0% during the 3rd quarter. State Street Corp now owns 4,253,217 shares of the company’s stock worth $20,586,000 after acquiring an additional 903,809 shares during the period. Finally, Jacobs Levy Equity Management Inc. lifted its holdings in shares of Verve Therapeutics by 72.2% during the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 1,559,393 shares of the company’s stock worth $7,547,000 after acquiring an additional 653,578 shares during the period. 97.11% of the stock is owned by institutional investors and hedge funds.

About Verve Therapeutics

Verve Therapeutics, Inc, a clinical stage genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases in the United States. The company's lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver; and VERVE-102, a product candidate that targets the PCSK9 gene for the treatment of HeFH.